CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Amgen AMGN

Verkoop
 Koop

Amgen live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Amgen news

number1 2025 Jul 11, 03:38

AI Podcast: Dollar Weakness and Investment Implications

number1 2025 Jul 11, 03:38

HSBC: Three 'Painful Trade' Risks Loom if Wall Street Gets It Wrong

Frances Wang 2024 Nov 26, 16:00

Stock Market Today: S&P 500 and Dow Reach New High On Trump’s Tariff Policy

Stocks
Frances Wang 2024 Aug 04, 16:00

The Week Ahead: ISM services, SMCI

CFD Trading
Australian dollar shrugs at RBA decision to keep interest rates unchanged
Georgy Istigechev 2024 Aug 03, 21:00

Week ahead: RBA meeting, Uber earnings, and PMIs

CFD Trading Forex
Disney is catching up with Netflix
Neil Wilson 2024 Feb 01, 08:03

Week ahead: Earnings season climax

Forex Indices
Bank of England BoE
Neil Wilson 2023 Oct 27, 10:00

Week ahead: Fed, Bank of England seen on pause; Apple earnings

Forex Indices

Laatste marktnieuws

Toon meer
number1 2025 Oct 21, 00:00

Zelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks

number1 2025 Oct 21, 00:00

Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets

number1 2025 Oct 21, 00:00

US Government Shutdown: Economic Fallout and Political Impasse

number1 2025 Oct 21, 00:00

Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty

number1 2025 Oct 19, 00:00

Global Market Overview: Precious Metals Surge Amidst Economic Uncertainty

number1 2025 Oct 18, 00:00

Japan LDP-Ishin Policy Talks: Paving the Way for a New Prime Minister?

number1 2025 Oct 18, 00:00

Israel Prepares to Reopen Rafah Crossing Amid Ceasefire Violation Claims

number1 2025 Oct 18, 00:00

Fed's Rate Cut Conundrum: An Outlook to 2026

Info

Spread

2.09

Spread (%)

0.6167 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Vrijdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

183169581056

Uitstaande aandelen

538480671

Datum winstcijfer (volgende)

1999-11-22

Div. rend.

2025-12-12

Ex-dividenddatum

2025-11-21

Jaarlijks verwachte dividendpercentage

9.52

Jaarlijks verwachte dividendrendement

0.0276

Winst per aandeel

12.92

Meer informatie over dit instrument

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten

latest_education_articles

Toon meer
Frances Wang 2025 Feb 17, 16:00

Pi network price prediction 2025: Will Pi Network price go up or down?

Stocks
Frances Wang 2025 Jan 21, 16:00

What is the XRP price prediction for 2025: Will XRP reach $1000?

Crypto
Frances Wang 2024 Dec 29, 16:00

What is the USD DXY index and how does the DXY reflect the dollar's value?

Indices
Trustpilot